CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
Navid Alipour, JD/MBA

Navid Alipour, JD/MBA

CEO

Navid Alipour is Co-founder and Managing Partner at Analytics Ventures, a Venture Formation Fund focused on starting new ventures with artificial intelligence and machine learning at their core.

Prior to co-founding Analytics Ventures, he founded La Costa Investment Group, making investments in startups nationally. Through the founding of multiple Artificial Intelligence (AI) based companies like CureMetrix and CureMatch, Navid is a long-time entrepreneur in the AI space and looks to address the need between angel investors and big venture capital funds. He has a passion for finding scientists and academics who are domain experts in their respective fields and helping them turn their research into viable businesses, helping build companies from inception.

Navid serves on the Board of Tech San Diego helping build the thriving eco-system in San Diego. He is also on the Board of CureMetrix, AV Lab, Kazuhm, Dynam.AI & AlphaTrAI. Navid is a sought-after panelist, judge, speaker, and moderator on the topics of venture capital and entrepreneurship at forums such as UCSD, USD, SDSU, CyberHive, HeraHub, MIT Forum, RSNA, U.S. News STEM Conference, and CONNECT. Navid holds a BA from UC San Diego, and a JD/MBA from the University of San Diego.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine Apr 6

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs Mar 28

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

  • CureMatch Names Life Sciences Executive David Szekeres as Board Director Feb 22

    CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data